Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11912165 | 1.00 | BRS3 (0.34) | BRS3GPR119DRD2MEN1KMT2A | |
| SCHEMBL2693885 | 0.87 | GPR119 (0.33) | BRS3GPR119DRD2MEN1KMT2A | |
| SCHEMBL4133054 | 0.87 | GPR119 (0.33) | BRS3GPR119DRD2MEN1KMT2A | |
| SCHEMBL2693491 | 0.86 | KMT2A (0.34) | BRS3GPR119DRD2MEN1KMT2A | |
| SCHEMBL4126871 | 0.86 | KMT2A (0.34) | BRS3GPR119DRD2MEN1KMT2A | |
| SCHEMBL17115521 | 0.86 | GPR119 (0.34) | BRS3GPR119DRD2MEN1KMT2A | |
| SCHEMBL9607183 | 0.86 | BRS3 (0.32) | BRS3MEN1KMT2AALOX5 | |
| SCHEMBL4132194 | 0.86 | BRS3 (0.32) | BRS3MEN1KMT2AALOX5 | |
| SCHEMBL15588713 | 0.86 | BRS3 (0.32) | BRS3MEN1KMT2AALOX5 | |
| SCHEMBL1711559 | 0.86 | BRS3 (0.32) | BRS3MEN1KMT2AALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2015-11-05 | — | — | US | disclosed |
| US-9079889-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2015-07-14 | — | — | US | disclosed |
| US-8829193-B2 | PIM kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2014-03-20 | — | — | US | disclosed |
| EP-2262802-B1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2596790-A1 | Pim kinase inhibitors and methods of their use | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8329732-B2 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | BURGER MATTHEW T (US) | 2012-05-31 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| EP-2262802-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | Novartis AG (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| WO-2009109576-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079693-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | BRS3 4063/4885GPR119 1963/4885DRD2 4786/4885 |
| US-20120134987-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | BRS3 4063/4885GPR119 1963/4885DRD2 4786/4885 |
| US-20100056576-A1 | Kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | BRS3 4063/4885GPR119 1963/4885DRD2 4786/4885 |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | BRS3 4027/4885GPR119 1000/4885DRD2 4742/4885 |
| US-20150315150-A1 | KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | BRS3 4063/4885GPR119 1963/4885DRD2 4786/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | BRS3 4027/4885GPR119 1000/4885DRD2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.